Get the Stockscreener App
4.851
6.30%
-0.3261
Cns Pharmaceuticals Inc stock is traded at $4.851, with a volume of 13,302.
It is down -6.30% in the last 24 hours and down -11.80% over the past month.
CNS Pharmaceuticals Inc is a biotechnology company focused on developing therapies for serious diseases in neurology and oncology. The company is building a high-value pipeline for neurology and oncology indications. Its new corporate includes pivoting from a singular focus on glioblastoma multiforme and exploring out-licensing opportunities for its legacy assets, TPI 287 and Berubicin.
See More
Previous Close:
$5.1771
Open:
$4.98
24h Volume:
13,302
Relative Volume:
2.23
Market Cap:
$7.09M
Revenue:
Net Income/Loss:
$-16.49M
P/E Ratio:
-0.1637
EPS:
-29.6295
Net Cash Flow:
$-15.24M
1W Performance:
-9.33%
1M Performance:
-11.80%
6M Performance:
+82.37%
1Y Performance:
-48.88%
1-Day Range:
$4.65
$5.00
1-Week Range:
$4.65
$5.40
52-Week Range:
$1.90
$10.54
Cns Pharmaceuticals Inc Stock (CNSP) Company Profile
Name
Cns Pharmaceuticals Inc
Sector
Industry
Phone
1-800-946-9185
Address
2100 WEST LOOP SOUTH, HOUSTON
Compare CNSP vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNSP
Cns Pharmaceuticals Inc
|
4.851 | 7.09M | 0 | -16.49M | -15.24M | -29.63 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cns Pharmaceuticals Inc Stock (CNSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-24-20 | Initiated | Ladenburg Thalmann | Buy |
Cns Pharmaceuticals Inc Stock (CNSP) Latest News
CNSP: Cns Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
With 45.72% of shares represented, CNS Pharmaceuticals (CNSP) wins approval to expand its stock plan. - Stock Titan
CNS Pharmaceuticals, Inc.Common Stock (NQ: CNSP - The Chronicle-Journal
PVG Sends Open Letter to Anavex Stockholders Detailing the Need for Change at the Company - globenewswire.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
CNS Pharmaceuticals (CNSP) Outlines Strategic Shift Amid Unprofi - GuruFocus
A biotech is seeking cancer or brain therapies. CNS Pharmaceuticals lays out its plan. - Stock Titan
CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference - Weatherford Democrat
CNS Pharmaceuticals CEO highlights new leadership team and strategy - Stock Titan
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com South Africa
Vertical Data: Downs Most Recently Served as CFO of CNS Pharmaceuticals >VDTA - Moomoo
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock - Investing.com
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com Canada
CNS Pharmaceuticals (CNSP) director buys 2,000 shares in open-market trade - Stock Titan
CNS Pharmaceuticals (CNSP) CEO converts 4,750 RSUs to stock - Stock Titan
CNS Pharmaceuticals (CNSP) lists director Michal with no reported trades - Stock Titan
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com UK
CNS Pharmaceuticals director Michal Fisher buys $10,000 in stock By Investing.com - Investing.com India
Central Nervous System (CNS) Lymphoma Market Outlook Signals Expansion To $2.08 Billion Through 2030 - openPR.com
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Trade Setups - vinanet.vn
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesSwing Entry Signals - dars.gov.et
CNS Pharmaceuticals (CNSP) Climbs 7.18% to $5.52 as Biotech Buying Pressure IntensifiesHead and Shoulders - dars.gov.et
Ikarian Capital (CNSP) discloses 9.9% beneficial ownership in CNS Pharmaceuticals - Stock Titan
CNSP Q2 2026 Earnings: Wider-than-Expected Loss of -$0.38 per Share Amid Clinical-Stage OperationsNet Profit Margin - vinanet.vn
CNS Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
CNS PHARMACEUTICALS ($CNSP) Releases Q2 2026 Earnings - Moomoo
CNS Pharmaceuticals Q2 net loss widens, cash rises after financing - TradingView
CNSP: Accelerated transformation and strong cash position support pipeline expansion and strategic growth - TradingView
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - accessnewswire.com
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - Corsicana Daily Sun
CNS Pharmaceuticals, Inc. Q2 2026: Net loss $2.59M, EPS $(0.38) — 10-Q Summary - TradingView
CNS Pharmaceuticals Reports Second Quarter 2026 Results, Highlighting Strengthened Balance Sheet and Accelerated Execution of Strategic Transformation - Yahoo Finance
CNS Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
CNSP Q1 2026 Earnings: Loss of $7.30 Per Share Misses Estimates as Pre-Revenue Pipeline Spend Rises - vinanet.vn
CNS Pharmaceuticals Inc (CNSP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Supernus, Indivior Announce Merger to Create $2.2 Billion CNS - vohnetwork.com
Supernus and Indivior Agree to $2.2 Billion Revenue Merger to Create CNS Biopharma Leader - citybiz
Supernus and Indivior merge to create CNS mega-company with 11 approved drugs - BioSpace
Supernus, Indivior merge to create CNS-focused company and expand BD opportunities - Fierce Pharma
Supernus Pharmaceuticals and Indivior Pharmaceuticals to - GlobeNewswire
Supernus and Indivior to Merge, Forming a New CNS-Focused Pharma Company - MedCity News
Cerenome Launches as an Integrated CNS Oncology Company - GlobeNewswire
Cerenome will combine CNS cancer diagnostics, treatments and AI Aug. 3 - Stock Titan
CNS Pharmaceuticals Inc (CNSP) Cash Flow - TradingKey
CNS Pharmaceuticals Inc (CNSP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CNS Pharmaceuticals Inc (CNSP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CNS Pharmaceuticals Inc (CNSP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
CNSP|CNS Pharmaceuticals Inc|Price:5.230|Chg%:-0.160 - TradingKey
CNS Pharmaceuticals Inc (CNSP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cns Pharmaceuticals Inc Stock (CNSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cns Pharmaceuticals Inc Stock (CNSP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Charles Faith L. | Director |
May 18 '26 |
Buy |
4.79 |
7,100 |
34,002 |
7,100 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):